MarketScreener Homepage > Equities > London Stock Exchange > GlaxoSmithKline plc GSK GB0009252882

Report

Real-time Estimate CHI-X - 02/25 11:30:00 am
1225.1	GBX		+1.00%

05:10p

GLAXOSMITHKLINE : Study on Otilimab for Treatment of Hospitalized Patients with COVID-19 Misses Primary Endpoint

02:52p

GLAXOSMITHKLINE : Study on Otilimab for Treatment of Hospitalized Adult Patients with COVID-19 Misses Primary Endpoint

08:11a

GLAXOSMITHKLINE : GSK to Assess Efficacy of COVID-19 Monoclonal Antibody Treatment in Patients Over 70

Summary

Quotes 5-day view Delayed Quote.

Delayed London Stock Exchange

02/19/2021	02/22/2021	02/23/2021	02/24/2021	02/25/2021	Date
1215.2(c)	1205.4(c)	1214.8(c)	1213(c)	1216	Last
13 360 499	12 322 245	9 729 702	7 860 276	6 016 905	Volume
-1.92%	-0.81%	+0.78%	-0.15%	+0.25%	Change

More quotes

Financials

Sales 2020	34 076 M 47 819 M 47 819 M
Net income 2020	4 894 M 6 868 M 6 868 M
Net Debt 2020	22 676 M 31 821 M 31 821 M
P/E ratio 2020	12,5x
Yield 2020	6,60%

Sales 2021	34 056 M 47 791 M 47 791 M
Net income 2021	3 474 M 4 874 M 4 874 M
Net Debt 2021	21 652 M 30 385 M 30 385 M
P/E ratio 2021	17,5x
Yield 2021	6,56%

Capitalization	60 694 M 85 740 M 85 173 M
EV / Sales 2020	2,45x
EV / Sales 2021	2,42x
Nbr of Employees	99 437
Free-Float	92,5%

More Financials

Company

GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%); - OTC and parapharmaceutical medicine (26.7%); - vaccines (21.2%); - other (0.1%). Net sales are distributed geographically as...

Sector

Pharmaceuticals

Calendar

04/28

Earnings Release

More about the company

Notations Surperformance© of GlaxoSmithKline plc

Trading Rating :

Investor Rating :

More Ratings

All news about GLAXOSMITHKLINE PLC

05:10p	GLAXOSMITHKLINE : Study on Otilimab for Treatment of Hospitalized Patients with ..	MT
02:52p	GLAXOSMITHKLINE : Study on Otilimab for Treatment of Hospitalized Adult Patients..	MT
08:11a	GLAXOSMITHKLINE : GSK to Assess Efficacy of COVID-19 Monoclonal Antibody Treatme..	MT
07:22a	GSK narrows focus on elderly in trial to treat pneumonia from COVID-19	RE
07:14a	GLAXOSMITHKLINE : Covid-19 Antibody Study Didn't Meet Primary Endpoint	DJ
07:06a	GLAXOSMITHKLINE : GSK announces results evaluating its investigational monoclona..	PU
02/24	GRANULES INDIA : Gets US FDA Nod For Migraine Treatment Drug	MT
02/24	GLAXOSMITHKLINE : GSK Unit ViiV Seeks FDA Approval for Expanded Use of HIV-1 Inf..	MT
02/24	GLAXOSMITHKLINE : ViiV Healthcare Seeks FDA Approval for Expanded Use of HIV-1 I..	MT
02/22	GLAXOSMITHKLINE : GSK and Sanofi start with new COVID-19 vaccine study after set..	RE
02/22	SANOFI : GlaxoSmithKline Initiate Phase 2 Study of COVID-19 Vaccine to Identify ..	MT
02/22	GLAXOSMITHKLINE : GSK, Sanofi Begin Phase Two Of Protein-Based COVID-19 Vaccine ..	MT
02/22	SANOFI : GSK Start New Covid-19 Vaccine Study After Setback	DJ
02/22	GSK and Sanofi start with new COVID-19 vaccine study after setback	RE
02/22	SANOFI : GSK Start New Phase 2 Study Of Adjuvanted Recombinant Protein-Based COV..	RE

More news

News in other languages on GLAXOSMITHKLINE PLC

10:51a	GSK : résultats mitigés pour un traitement contre le Covid
08:42a	40 femmes d’affaires qui comptent en Europe
07:21a	GLAXOSMITHKLINE : Corona-Antikörper von GlaxosmithKline verfehlt Studienziel
02/23	LONDON STOCK EXCHANGE : Coronavirus-Le Royaume-Uni recense 548 décès et 8.489 no..
02/23	COVID-19 : jeu de chaises musicales dans l’industrie pharmaceutique

More news

Analyst Recommendations on GLAXOSMITHKLINE PLC

02/16	GLAXOSMITHKLINE : Sell rating from Deutsche Bank	MD
02/12	GLAXOSMITHKLINE : Morgan Stanley Keeps GSK at Equalweight, Trims PT	MT
02/11	GLAXOSMITHKLINE : Berenberg Keeps GSK at Buy, Lowers PT	MT

More recommendations

Provided by Scoopnest.com

Analysis

GlaxoSmithKline : Sanofi's mRNA COVID-19 vaccine candidate not ready this year, CEO says

More Must read

Chart GLAXOSMITHKLINE PLC

Duration : Period :

GlaxoSmithKline plc Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends GLAXOSMITHKLINE PLC

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bearish	Bearish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	26
Average target price	1 567,63 GBX
Last Close Price	1 213,00 GBX
Spread / Highest target	93,7%
Spread / Average Target	29,2%
Spread / Lowest Target	-20,5%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Emma N. Walmsley	Chief Executive Officer & Executive Director
Iain James Mackay	Chief Financial Officer & Executive Director
Jonathan Richard Symonds	Non-Executive Chairman
Karenann K. Terrell	Chief Digital & Technology Officer
Hal V. Barron	Executive Director & Chief Scientific Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

GLAXOSMITHKLINE PLC	-9.61%	85 313



JOHNSON & JOHNSON	3.31%	427 397
ROCHE HOLDING AG	-2.09%	285 788
NOVARTIS AG	-5.12%	197 223
ABBVIE INC.	1.44%	191 934
MERCK & CO., INC.	-8.84%	188 665

More Results